Vaccinations for Patients with Rheumatic Diseases - RA, AS, PSA, SLE.

MedMaven

by Drs. David Borenstein M.D. & C.H. Weaver M.D. Executive Editors 3/2020

Vaccination and immunization play an important part in the management of patients with autoimmune inflammatory rheumatic diseases (AIIRD) who are at increased risk for infections as a result of their underlying condition, associated comorbidities, and immunosuppressive therapy, including glucocorticoids and disease-modifying antirheumatic drugs (DMARDs). 1

Rheumatic disease patients including those with rheumatoid arthritis and ankylosing spondylitis are at risk for infections compared to a normal population of people. In addition to their underlying disease, some of the therapies used for these conditions [disease-modifying drugs (DMARDs) and biologics] may also increase the risk of infection.

Vaccinations are a well-established means of decreasing the risk of certain infections. However, the characteristics of the vaccine (live versus dead) and the medicines a patient is taking can have an effect on whether the vaccine will be effective. Modification of the immune response by DMARDs and biologics can minimize the booster effect of the vaccine. The timing of administration is also important in getting the maximum benefit.

When a patient starts treatment they should discuss an overall vaccine plan with their doctor and possibly holding off on starting a medication to ensure the vaccines can be effective. (6)

Vaccinations and AIIRD

Patients with rheumatic diseases may receive live vaccines.

Live vaccines may be safely administered in adult patients receiving prednisone, methotrexate azathioprine, or mercaptopurine according to the Advisory Committee on Immunization Practices (ACIP). (1,9,10) All live vaccines, including measles and zoster, should be administered to patients greater than 4 weeks before starting immunosuppressive therapy, except in circumstances where risks outweigh vaccination benefits. (8)

Patients with rheumatic diseases should avoid close contact with family members or others who have been vaccinated with live vaccines; however, this should not deter any individual with or without immunosuppression from receiving the recommended vaccines. (6)

Live vaccines are typically contraindicated in pregnant women with rheumatic diseases because the mild infection they produce may affect the fetus. (5)Live-attenuated vaccines should also be avoided for 6 months after delivery in mothers who have been treated with biologics during the second half of their pregnancy.(1)

Coronavirus

The 2019 novel coronavirus (2019-nCoV) is a new virus that causes respiratory illness in people and can spread from person-to-person. This virus was first identified during an investigation into an outbreak in Wuhan, China and has quickly spread throughout China and to 31 other countries including the United States. Individuals with weakened immune systems such as patients on immunosuppressive medications for the treatment of Rheumatoid Arthritis, Psoriatic Arthritis or Ankylosing Spondylitis might be at higher risk for infection and complications associated with the virus that causes COVID illness. There is currently no vaccine but one is in development.

Vaccine Progress: There are ~ 70 vaccines in various stages of development, most in pre-clinical trials (animal studies to assess immune response), and there are three vaccines currently in clinical human trials, with initial results expected late Summer or early Fall:

  • Moderna (Cambridge, MA): This was the first vaccine to be studied in humans with the first person receiving it in Seattle in March.
  • Inovio Pharmaceuticals (San Diego CA): One trial is underway at the University of Pennsylvania and a second trial of their vaccine is about to begin in South Korea.
  • CanSino Biological (Wuhan, China): Phase 1 completed in March, Phase 2 starting in April to look for adverse response and for antibody responses

What you need to know about Coronavirus

Influenza

Influenza "Flu" is a seasonal viral infection that commonly occurs during the winter months beginning in November.

Flu vaccines are generally safe and effective for patients with AIIRD

Compared with the general population, patients with AIIRD have increased mortality and from vaccine-preventable illnesses such as influenza (7) therefore patients should receive the seasonal influenza vaccine annually, except in cases where contraindicated. Patients are also advised to receive the flu vaccine before starting immunosuppressive therapy or if they are immunosuppressed. (8)

Influenza is an inactivated virus vaccine that is appropriate for all rheumatology patients to receive annually. The high dose flu vaccine does offer greater protective amounts of anti-influenza antibodies than standard dose. The guess every year is the type of influenza virus that is included in the vaccine. Different strains are included each year. Some years work better than others. For example, in 2020, the influenza vaccine was 50% effective.

Methotrexate is a DMARD that is used to treat rheumatoid arthritis and spondyloarthritis. This drug can blunt the response to vaccines. That is the case with influenza vaccine. It is recommended that methotrexate be stopped for 2 weeks after the vaccine is administered in order to receive optimal benefit.

Understanding Influenza Vaccines

Patients with egg allergies may receive an egg-free vaccine for active immunization against influenza A and B.(9)

All children, including those with rheumatic disease, are recommended to receive annual vaccination against influenza. According to a review, no difference in local and systemic tolerability of the flu vaccine was seen among healthy children vs those with rheumatic diseases. (2)

Pneumococcal Disease

Pneumococcal bacteria can cause pneumonia and other infections. Optimal vaccination against pneumococcal disease consists of the Pneumovax and Prevnar13 vaccine. Vaccination is appropriate for all individuals with chronic diseases and adults over 65 years of age.

Patients with AIIRD who may be starting or are currently receiving immunosuppressive therapy are strongly recommended to receive the Prevnar13-valent pneumococcal vaccine (PCV13) to protect against Streptococcus pneumonia and then the Pneumovax 23-valent pneumococcal polysaccharide vaccine (PPSV23) after ≥8 weeks. (8) The timing of pneumococcal vaccination is crucial. If patients with rheumatic disease receive PPSV23 first, PCV13 must be administered greater than 1 year later, whereas if Prevnar is given first, Pneumonvax may be administered only 2 months later. (9)

Both vaccines are ideally administered at least 2 weeks before initiation of immunosuppressive therapy; however, if vaccination is not possible before starting immunosuppressive medications, the pneumococcal vaccines should be administered as soon as possible and/or when immunosuppression is low. With regard to booster doses for Pneumovax recommendations vary among but revaccination with Prevnar13 is not required. (8)

The Prevnar13 vaccine is helpful for preventing pneumococcal community-acquired pneumonia Prevnar is usually given first followed by Pneumovax 1 year later. Similar to the influenza vaccine, methotrexate needs to be stopped for 2 weeks after the inoculation. Anti-tumor necrosis factor biologic medications do not need to be discontinued. Other biologics like rituximab and Janus Kinase inhibitors need to be stopped.

Shingles

Chickenpox is a viral infection that was common in children before a vaccine was developed to prevent the illness. Individuals who were exposed to chickenpox are at risk of a reemergence of the virus. This reemergence is called herpes zoster or “shingles.” Shingles causes a painful rash that usually develops in a single stripe on one side of the body or face. The condition can affect anyone who’s had chickenpox but is most common in older people or those with a weakened immune system. People with immune-mediated conditions such as RA are also at increased risk of shingles.

The U.S. Food and Drug Administration (FDA) has approved two vaccines to prevent shingles: Zostavax and Shingrix. Zostavax is a live vaccine. This means it contains a weakened form of the virus. Shingrix vaccine is a recombinant vaccine. This means vaccine manufacturers created it by altering and purifying DNA that codes for an antigen to produce an immune response to fight the virus. The Shingrix vaccine as the preferred option whenever possible. Shingrix is more effective and likely longer lasting than the Zostavax vaccine in preventing shingles. effective in preventing postherpetic neuralgia. Patients should discuss the role of the “shingles” vaccine with their physician.

Shingles – DMARDS and Biologics

Shingrex vaccination against “shingles”

References:

  1. Furer V, Rondaan C, Heijstek MW, et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2020;79(1):39-52.
  2. Dell’Era L, Esposito S, Corona F, Principi N. Vaccination of children and adolescents with rheumatic diseases. Rheumatology (Oxford). 2011;50(8):1358-1365.
  3. World Health Organization. World Immunization Week 2020. Accessed April 26, 2020.
  4. World Health Organization. Update on WHO solidarity trial – accelerating a safe and effective COVID-19 vaccine. Accessed April 25, 2020.
  5. Hospital for Special Surgery. Vaccinations and rheumatic disease. Updated January 10, 2011. Accessed April 26, 2020.
  6. Collins TR. Vaccines & rheumatology patients. The Rheumatologist website. Published June 12, 2019. Accessed April 26, 2020.
  7. Westra J, Rondaan C, van Assen S, Bijl M. Vaccination of patients with autoimmune inflammatory rheumatic diseases. Nat Rev Rheum. 2015;11:135-145.
  8. Kotton CN, Winthrop KL. Immunizations in autoimmune inflammatory rheumatic disease in adults. UpToDate website. Updated February 11, 2020. Accessed April 26, 2020.
  9. Dao KH. Top 5 things rheumatologists should know about vaccines. RheumNow website. Published May 6, 2015. Accessed April 28, 2020.
  10. Centers for Disease Control and Prevention. Vaccine recommendations and guidelines of the ACIP. Updated March 30, 2020. Accessed April 26, 2020.
Comments

Rheumatoid Arthritis

FEATURED
COMMUNITY